Interleukin (il)-6 And Receptor Activator Of Nuclear Factor (nf)-Kappab Ligand (rankl) Are Increased In The Serum Of A Patient With Primary Pachydermoperiostosis
Interleukin (il)-6 And Receptor Activator Of Nuclear Factor (nf)-Kappab Ligand (rankl) Are Increased In The Serum Of A Patient With Primary Pachydermoperiostosis(357 views visite) Rendina D, De Filippo G, Viceconti R, Soscia E, Sirignano C, Salvatore M, Della Monica M, Scarano G, Mossetti G
Keywords Parole chiave: Interleukin 6, Osteoclast Differentiation Factor, Tnfsf11 Protein, Human, Alkaline Phosphatase Bone Isoenzyme, Colchicine, Nonsteroid Antiinflammatory Agent, Technetium 99m, Adolescent, Article, Blood, Case Report, Osteoarthropathy, Radiography, Scintiscanning, Adult, Anamnesis, Bone Scintiscanning, Bone Turnover, Capillaroscopy, Clinical Feature, Hormone Blood Level, Nuclear Magnetic Resonance Imaging, Osteolysis, Physical Examination, Primary Pachydermoperiostosis, Priority Journal, Primary Hypertrophic, Rank Ligand,
Affiliations Affiliazioni: *** IBB - CNR ***
Department of Clinical and Experimental Medicine, 'Federico II' University Medical School, Naples, Italy Paediatric Endocrinology Unit, A.O.R.N. 'G. Rummo', Benevento, Italy Department of Biomorphological and Functional Science, Department of Diagnostic Imaging and Radiotherapy, 'Federico II' University Medical School, Naples, Italy National Research Council (CNR) Biostructures and Bioimaging Institute, 'Federico II' University Medical School, Naples, Italy Medical Genetics Unit, A.O.R.N. 'G. Rummo', Benevento, Italy
References Riferimenti: Castori, M., Sinibaldi, L., Mingarelli, R., Lachman, R.S., Rimoin, D.L., Dallapiccola, B., Pachydermoperiostosis: An update (2005) Clin Gen, 68, pp. 477-48
Auger, M., Stavrianeas, N., Pachydermoperiostosis (2004) Orphanet encyclopedia, , www.orpha.net, Available from:, accessed December 2006
White, M.P., Hereditary metabolic and dysplastic skeletal disorders (2002) Disorders of bone and mineral metabolism, pp. 937-985. , Coe FL, Favus MJ, editors, 2nd edn. Philadelphia: Lippincott, Williams & Wilkins
Jajic, Z., Jajic, I., Nemcic, T., Primary hypertrophic osteoarthropathy: Clinical, radiologic, and scintigraphic characteristics (2001) Arch Med Res, 32, pp. 136-142
Jajic, I., Jajic, Z., Grazio, S., Minor but important symptoms and signs in primary hypertrophic osteoarthropathy (2001) Clin Exp Rheumatol, 19, pp. 357-358
Hughes, H.E., McAlpine, P.J., Cox, D.W., Philipps, S., An autosomal dominant syndrome with 'acromegaloid' features and thickened oral mucosa (1985) J Med Genet, 22, pp. 119-125
Pichler, G., Eber, E., Thalhammer, G., Muntean, W., Zach, M.S., Arthralgia and digital clubbing in a child: Hypertrophic osteoarthropathy with inflammatory pseudotumour of the lung (2004) Scand J Rheumatol, 33, pp. 189-191
Oikarinen, A., Palatsi, R., Kylmaniemi, M., Keski-Oja, J., Risteli, J., Kallioinen, M., Pachydermoperiostosis: Analysis of the connective tissue abnormality in one family (1994) J Am Acad Dermatol, 31, pp. 947-953
Silveri, F., De Angelis, R., Argentati, F., Brecciaroli, D., Muti, S., Cervini, C., Hypertrophic osteoarthropathy: Endothelium and platelet function (1996) Clin Rheumatol, 15, pp. 435-439
Silveira, L.H., Martinez-Lavin, M., Pineda, C., Fonseca, M.C., Navarro, C., Nava, A., Vascular endothelial growth factor and hypertrophic osteoarthropathy (2000) Clin Exp Rheumatol, 18, pp. 57-62
Matucci-Cerinic, M., Martinez-Lavin, M., Rojo, F., Fonseca, C., Kahaleh, B.M., von Willebrand factor antigen in hypertrophic osteoarthropathy (1992) J Rheumatol, 19, pp. 765-767
Fam, A.G., Chin-Sang, H., Ramsay, C.A., Pachydermoperiostosis: Scintigraphic, thermographic, plethysmographic, and capillaroscopic observations (1983) Ann Rheum Dis, 42, pp. 98-102
Kallen, K.J., The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases (2002) Biochim Biophys Acta, 1592, pp. 323-334
Jostock, T., Mullberg, J., Ozbek, S., Atreya, R., Blinn, G., Voltz, N., Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses (2001) Eur J Biochem, 268, pp. 160-167
Boyle, W.J., Simonet, W.S., Lacey, D.L., Osteoclast differentiation and activation (2003) Nature, 423, pp. 337-342
Franchimont, N., Wertz, S., Malaise, M., Interleukin-6: An osteotropic factor influencing bone formation? (2005) Bone, 37, pp. 601-606
Jones, S.A., Rose-John, S., The role of soluble receptors in cytokine biology: The agonistic properties of the sIL-6R/IL-6 complex (2002) Biochim Biophys Acta, 1592, pp. 251-263
Kwan Tat, S., Padrines, M., Theoleyre, S., Heymann, D., Fortun, Y., IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology (2004) Cytokine Growth Factor Rev, 15, pp. 49-60
Mossetti, G., Rendina, D., De Filippo, G., Viceconti, R., Di Domenico, G., Cioffi, M., Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: Relationship to risedronate treatment (2005) Bone, 36, pp. 549-554
Angelo, L.S., Kurzrock, R., Vascular endothelial growth factor and its relationship to inflammatory mediators (2007) Clin Cancer Res, 13, pp. 2825-2830
Knudsen, L.S., Ostergaard, M., Baslund, B., Narvestad, E., Petersen, J., Nielsen, H.J., Plasma IL-6, plasma VEGF, and serum YKL-40: Relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate (2006) Scand J Rheumatol, 35, pp. 489-491
Brandi, M.L., Collin-Osdoby, P., Vascular biology and the skeleton (2006) J Bone Miner Res, 21, pp. 183-192
Roodman, G.D., Treatment strategies for bone disease (2007) Bone Marrow Transplant, 4, pp. 1139-1146
White, M. P., Hereditary metabolic and dysplastic skeletal disorders (2002) Disorders of bone and mineral metabolism, pp. 937-985. , Coe FL, Favus MJ, editors, 2nd edn. Philadelphia: Lippincott, Williams & Wilkins
Hughes, H. E., McAlpine, P. J., Cox, D. W., Philipps, S., An autosomal dominant syndrome with 'Acromegaloid' features and thickened oral mucosa (1985) J Med Genet, 22, pp. 119-125
Silveira, L. H., Martinez-Lavin, M., Pineda, C., Fonseca, M. C., Navarro, C., Nava, A., Vascular endothelial growth factor and hypertrophic osteoarthropathy (2000) Clin Exp Rheumatol, 18, pp. 57-62
Fam, A. G., Chin-Sang, H., Ramsay, C. A., Pachydermoperiostosis: Scintigraphic, thermographic, plethysmographic, and capillaroscopic observations (1983) Ann Rheum Dis, 42, pp. 98-102
Kallen, K. J., The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases (2002) Biochim Biophys Acta, 1592, pp. 323-334
Boyle, W. J., Simonet, W. S., Lacey, D. L., Osteoclast differentiation and activation (2003) Nature, 423, pp. 337-342
Jones, S. A., Rose-John, S., The role of soluble receptors in cytokine biology: The agonistic properties of the sIL-6R/IL-6 complex (2002) Biochim Biophys Acta, 1592, pp. 251-263
Angelo, L. S., Kurzrock, R., Vascular endothelial growth factor and its relationship to inflammatory mediators (2007) Clin Cancer Res, 13, pp. 2825-2830
Knudsen, L. S., Ostergaard, M., Baslund, B., Narvestad, E., Petersen, J., Nielsen, H. J., Plasma IL-6, plasma VEGF, and serum YKL-40: Relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate (2006) Scand J Rheumatol, 35, pp. 489-491
Brandi, M. L., Collin-Osdoby, P., Vascular biology and the skeleton (2006) J Bone Miner Res, 21, pp. 183-192
Roodman, G. D., Treatment strategies for bone disease (2007) Bone Marrow Transplant, 4, pp. 1139-1146
Interleukin (il)-6 And Receptor Activator Of Nuclear Factor (nf)-Kappab Ligand (rankl) Are Increased In The Serum Of A Patient With Primary Pachydermoperiostosis
Interleukin (il)-6 And Receptor Activator Of Nuclear Factor (nf)-Kappab Ligand (rankl) Are Increased In The Serum Of A Patient With Primary Pachydermoperiostosis
No results. Nessun risultato.
Interleukin (il)-6 And Receptor Activator Of Nuclear Factor (nf)-Kappab Ligand (rankl) Are Increased In The Serum Of A Patient With Primary Pachydermoperiostosis
Kim YH, Shin SW, Pellicano R, Fagoonee S, Choi IJ, Kim YI, Park B, Choi JM, Kim SG, Choi J, Park JY, Oh S, Yang HJ, Lim JH, Im JP, Kim JS, Jung HC, Ponzetto A, Figura N, Malfertheiner P, Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH, Bae SE, Choi KD, Choe J, Kim SO, Na HK, Choi JY, Ahn JY, Jung KW, Lee J, Kim DH, Chang HS, Song HJ, Lee GH, Jung HY, Seta T, Takahashi Y, Noguchi Y, Shikata S, Sakai T, Sakai K, Yamashita Y, Nakayama T, Leja M, Park JY, Murillo R, Liepniece-karele I, Isajevs S, Kikuste I, Rudzite D, Krike P, Parshutin S, Polaka I, Kirsners A, Santare D, Folkmanis V, Daugule I, Plummer M, Herrero R, Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X, Corral JE, Mera R, Dye CW, Morgan DR, Lee YC, Lin JT, Garcia Martin R, Matia Cubillo A, Lee SH, Park JM, Han YM, Ko WJ, Hahm KB, Leontiadis GI, Ford AC, Ichinose M, Sugano K, Jeong M, Park JM, Han YM, Park KY, Lee DH, Yoo JH, Cho JY, Hahm KB, Bang CS, Baik GH, Shin IS, Kim JB, Suk KT, Yoon JH, Kim YS, Kim DJ * Helicobacter pylori Eradication for Prevention of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer(211 visite) N Engl J Med (ISSN: 0028-4793, 0028-4793linking, 1533-4406electronic), 2015 Jun; 30642104201566393291: 749-756. Impact Factor:59.558 DettagliEsporta in BibTeXEsporta in EndNote
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(544 visite) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 DettagliEsporta in BibTeXEsporta in EndNote
164 Records (158 escludendo Abstract e Conferenze). Impact factor totale: 555.467 (544.872 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 593.827 (581.562 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Marco Comerci on in data Sunday 12 July 2020, 13:15:03 357 views visite. Last view on Ultima visita in data Friday 22 January 2021, 23:07:07